Transcription factor activator protein 4 (AP4)–mediated intrinsic control of axon regeneration
Brief intro:
- Author: Ngan Pan Bennett Au, Yumeng Gan, Xinyu Chen, Fuying Gao, Christopher Kai-Shun Leung, and Chi Him Eddie Ma
- Journal: SCIENCE ADVANCES
- Doi: https://www.doi.org/10.1126/sciadv.adu3917
- Publication Date: 2025/10/29
Abstract
Activator protein 4 (AP4) is a basic helix-loop-helix leucine-zipper transcription factor, a direct transcriptional target of c-Myc and a key regulator of cell growth and apoptosis, abundantly expressed in cancer cells. Here, we reveal a role for the c-Myc–AP4 axis in axon regeneration and the intrinsic growth capacity of injured neurons. Through bioinformatic and functional analyses, we demonstrated that overexpression of AP4 in mice not only accelerated in vivo axon regeneration and functional recovery after peripheral nerve injury but also promoted robust axon regeneration and neuronal survival after optic nerve injury by activating mammalian target of rapamycin activity. Neuronal-specific knockdown of AP4 abolished the regenerative phenotype induced by c-Myc overexpression and phosphatase and tensin homolog (PTEN) deletion. AP4 overexpression rendered the intrinsic growth capacity of c-Myc silencing injured retinal ganglion cells unaffected. These findings unveil a distinct aspect of the c-Myc–AP4 axis and highlight a previously unrecognized intrinsic role of AP4 in axon regeneration, with potential therapeutic implications.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.